Hemab Therapeutics Holdings Common Stock Total Liabilities

Hemab Therapeutics Holdings Common Stock posts a total liabilities of $370M as of March 2026. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

Total Liabilities is one piece of Hemab Therapeutics Holdings Common Stock's financial statement story. At $370M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for COAG's total liabilities usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Hemab Therapeutics Holdings Common Stock's other metric pages and overview cover the third.

Judging Hemab Therapeutics Holdings Common Stock against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in total liabilities easier to interpret. Start with $370M here, then scan peer and history charts to see if the gap is persistent.